$QNTM

Quantum BioPharma (TSX: QNTM) shares fell 5.75% on September 3, 2026, despite FDA clearance for its Lucid-MS program to advance to Phase 2 trials. The decline reflects investor caution about clinical execution risks, regulatory uncertainty, and funding pressures. The company's value hinges on successful development and commercialization of its pipeline, with Phase 2 trials being a key catalyst.

Quantum BioPharma (NASDAQ: QNTM) plans to delist its Class B shares from the Canadian Securities Exchange (CSE), citing low trading volume. The company will continue trading on Nasdaq, Frankfurt Stock Exchange, and Upstream. Quantum expects the move to reduce costs and improve liquidity. The delisting is subject to CSE approval, expected by September 4, 2026.

Quantum BioPharma's shares fell 4.44% on August 26, 2026, despite FDA clearance for a Phase 2 trial of its lead drug, Lucid-MS. The decline reflects clinical risks, profit-taking, and broader biotech volatility. The company's revenue depends on successful drug development, with no near-term earnings visibility. Investors focus on clinical progress and potential partnerships.

Quantum BioPharma (TSX: QNTM) shares fell 4.26% on August 25, 2026, despite FDA clearance for its Lucid-MS program to advance to Phase Two trials. The decline reflects investor uncertainty around clinical execution, funding, and commercialization risks. The company's value is tied to its development-stage biotech assets, with limited earnings visibility and high volatility.

Quantum BioPharma (QNTM) has received FDA clearance for a phase 2 trial of Lucid-MS, a therapy designed to protect myelin in multiple sclerosis patients. The drug aims to inhibit demyelination without suppressing the immune system, addressing an unmet need in MS treatment.

Citadel Advisors’ Q2 2026 13F shows new stakes in SpaceX, Cerebras Systems and Quantinuum, according to the filing. Citadel’s reported equity portfolio rose to $875.1B, up 41.5% from $618.5B in Q1 2026. The filing does not disclose share counts or entry prices. Cerebras is now public on Nasdaq under CBRS.

Quantum BioPharma (QNTM) reported Q2 2026 results and said FDA approval cleared its Lucid-MS IND to start a randomized, double-blind, placebo-controlled Phase 2 trial in progressive multiple sclerosis. Cash, cash equivalents and digital assets rose to about $9.5M (from $4.1M). Operating expenses fell 53% YoY to $2.29M.

Quantinuum (QNTM) shares fell about 4% to around $68 after Q2 revenue rose to about $8.0 million and bookings to about $4.3 million. The quarter’s GAAP net loss widened to $65.4 million, driven by a large IPO-related stock-based compensation charge. Full-year 2026 revenue guidance is $28 million to $32 million.

Quantum BioPharma Ltd. (QNTM) reported unaudited results for the three and six months ended June 30, 2026. Q2 net loss narrowed to $3.09M from $9.77M. Six-month net loss was $16.85M. Total assets rose to $14.39M, mainly from digital assets. The company raised $7.88M via ATM and issued $2.73M convertible debentures, increasing derivative and warrant liabilities.

Quantum BioPharma (QNTM) said the FDA cleared its IND for Lucid-MS, enabling the program to enter a Phase 2 multiple-sclerosis trial. The company also signed a binding LOI with Allucent to run the study. Despite the regulatory step, QNTM shares fell about 6.4% premarket to around $3.23, reflecting ongoing pre-revenue risk.